Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.
A 52 year -old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproliferative disorder.
O'Dwyer
M E
ME
Division of Hematology and Medical Oncology, Transplant Surgery Division and Department of Pathology, Oregon Health Sciences University, Portland, Oregon 97201, USA. odwyerm@ohsu.edu
Launder
T
T
Rabkin
J M
JM
Nichols
C R
CR
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000821:virology; D018572:Disease-Free Survival; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000821:virology; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000009:adverse effects*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab